Improving cancer immunotherapy by targeting the STATe of MDSCs

Nienke de Haas, Coco de Koning, Lisanne Spilgies, I. Jolanda M. de Vries, Stanleyson V. Hato

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

52 Citaten (Scopus)

Samenvatting

Cancer immunotherapy is a promising therapeutic avenue; however, in practice its efficacy is hampered by an immunosuppressive tumor microenvironment that consists of suppressive cell types like myeloid-derived suppressor cells (MDSCs). Eradication or reprogramming of MDSCs could therefore enhance clinical responses to immunotherapy. Here, we review clinically available drugs that target MDSCs, often through inhibition of STAT signaling, which is essential for MDSC accumulation and suppressive functions. Interestingly, several drugs used for non-cancerous indications and natural compounds similarly inhibit MDSCs by STAT inhibition, but have fewer side effects than anticancer drugs. Therefore, they show great potential for combination strategies with immunotherapy.

Originele taal-2Engels
Artikelnummere1196312
TijdschriftOncoImmunology
Volume5
Nummer van het tijdschrift7
DOI's
StatusGepubliceerd - 2 jul. 2016
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Improving cancer immunotherapy by targeting the STATe of MDSCs'. Samen vormen ze een unieke vingerafdruk.

Citeer dit